Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: G3NEC are heterogeneous and aggressive diseases which can arise in different organs. Platinum-etoposide combination is used as first line treatment whatever the primary. Rb has been suggested to be a predictive/prognostic factor.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Hadoux J
Authors: Hadoux J, Kanaan C, Planchard D, Malka D, Ducreux M,
Keywords: Neuroendocrine carcinoma, Platinum-etoposide, Rb,
Introduction: Pancreatic neuroendocrine carcinoma (p-NEC) with liver metastasis has a poor prognosis. The treatment is mainly chemotherapy which is now still a huge challenge on NEC with high ki-67 index.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Bai J
Keywords: Pancreatic neuroendocrine carcinoma, chemotherapy, Doxorubicin+mitomycin+loplatin, patient-derived tumor xenograft, Carbon ion,
Introduction: Metastatic WHO grade 3 extra-pulmonary neuroendocrine carcinomas (EP-NEC) have a poor prognosis and optimal treatment after first-line platinum-etoposide chemotherapy remains unclear. A recent, small phase II study combining ipilimumab and nivolumab showed promising results
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Vandamme T, De Backer L, Van den Brande J, Op de Beeck B, Driessen A,
Keywords: NEC, immunotherapy,
Introduction: DNA-targeting agents are the main treatment of aggressive pulmonary and pancreatic neuroendocrine carcinomas (NEC). FOXM1 is a transcription factor controlling cell proliferation and DNA repair pathways, playing therefore an important role in tumor progression and chemoresistance.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Cros J
Authors: De Rycke O, Raffenne J, Lacombe C, Hentic O, Gounant V,
Keywords: neuroendocrine carcinoma, FOXM1, DNA repair, anti-tumor drug,
Introduction: Etoposide-platinum (EP) chemotherapy has long stood as the reference treatment of grade 3 neuroendocrine neoplasms (G3 NEN). However, G3 NEN are heterogeneous, including well differentiated tumours (NET) and poorly differentiated carcinomas of large (LCNEC) or small (SCNEC) cell type, whose identification can be challenging and response to EP be very variable, usually low in NET.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Lacombe C, De Rycke O, Chen R, Colnot N, Hentic O,
Keywords: grade 3, chemotherapy, biomarkers, etoposide-platinum, pRb, p53,